These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29153547)

  • 1. Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
    Knerr PJ; Finan B; Gelfanov V; Perez-Tilve D; Tschöp MH; DiMarchi RD
    Bioorg Med Chem; 2018 Jun; 26(10):2873-2881. PubMed ID: 29153547
    [No Abstract]   [Full Text] [Related]  

  • 2. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
    Spasov AA; Chepljaeva NI
    Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.
    Will S; Hornigold DC; Baker DJ; Coghlan MP; Mesquita M; Trevaskis JL; Naylor J
    Curr Opin Pharmacol; 2017 Dec; 37():10-15. PubMed ID: 28802873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment of type 2 diabetes.
    Bloomgarden ZT
    Diabetes Care; 2003 Feb; 26(2):526-33. PubMed ID: 12547894
    [No Abstract]   [Full Text] [Related]  

  • 5. Gut hormone polyagonists for the treatment of type 2 diabetes.
    Brandt SJ; Götz A; Tschöp MH; Müller TD
    Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
    Knerr PJ; Mowery SA; Finan B; Perez-Tilve D; Tschöp MH; DiMarchi RD
    Peptides; 2020 Mar; 125():170225. PubMed ID: 31786282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes.
    Tschöp M; DiMarchi R
    Diabetes; 2017 Jul; 66(7):1766-1769. PubMed ID: 28603138
    [No Abstract]   [Full Text] [Related]  

  • 8. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutrient-induced secretion and metabolic effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Knapper JM; Morgan LM; Fletcher JM
    Proc Nutr Soc; 1996 Mar; 55(1B):291-305. PubMed ID: 8832801
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
    Kluz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Hydroxypyruvate: a new diabetogenic factor?
    Mizuno TM
    Diabetes; 2015 Apr; 64(4):1099-101. PubMed ID: 25805762
    [No Abstract]   [Full Text] [Related]  

  • 15. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy.
    Rieger TR; Musante CJ
    Eur J Pharm Sci; 2016 Oct; 94():15-19. PubMed ID: 27157042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD; Flatt PR
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving towards a more precise treatment of diabetes.
    Gruber K
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):171. PubMed ID: 25702247
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptide-based multi-agonists: a new paradigm in metabolic pharmacology.
    Brandt SJ; Müller TD; DiMarchi RD; Tschöp MH; Stemmer K
    J Intern Med; 2018 Dec; 284(6):581-602. PubMed ID: 30230640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.